A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Key Who May Qualify: - Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and diagnosed by tissue sample (biopsy-confirmed) with the following: - CLASI-A total score ≥ 10 points at Screening and confirmed at randomization. - Inadequate response or intolerant to antimalarial therapy. - Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result. - Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Key Who Should NOT Join This Trial: - History or evidence of suicidal ideation. - Severe or life-threatening Systemic lupus erythematosus (SLE). - Active SLE or Sjögren's Syndrome. - Any active skin conditions other than CLE that may interfere with the study. - History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS). - History of recurrent infection requiring hospitalization and IV antibiotics. - COVID-19 infection. - Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies. - At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply Always talk to your doctor about whether this trial is right for you.